Novo Nordisk’s oral Wegovy has reached three million U.S. prescriptions in five months, with over 80% of new patients new to GLP-1 therapy, signaling market expansion beyond injectables. Meanwhile, phase 3 data for CagriSema and phase 2 results for Zenagamtide were presented at ADA, and the company is exploring GLP-1 applications in aesthetic medicine. For overseas buyers and distributors, these developments indicate a broadening obesity treatment landscape and potential new product categories for clinic and pharmacy channels.
Market signal
Novo Nordisk closed at €37.27 on 6 June 2026, 46.86% below its 52-week high of €70.13. Despite strong commercial and clinical news, the stock remains tepid with an RSI of 48.3 and sits just above its 50-day moving average. The market’s indifference contrasts with the company’s rapid progress in oral GLP-1 uptake and pipeline milestones.
Oral Wegovy uptake and channel expansion
The Wegovy pill, launched in U.S. pharmacies and online in January 2026, has generated three million prescriptions in just over five months. The first million took twelve weeks; the next two million followed in ten weeks. Over 80% of new scripts came from patients new to GLP-1 therapy, suggesting the tablet is expanding the addressable market rather than cannibalizing injectable Wegovy. International rollout began on 3 June in the United Arab Emirates with the 25 mg dose, with further launches planned for H2 2026.
Pipeline progress and aesthetic medicine interest
At the American Diabetes Association meeting, Novo Nordisk presented full phase 3 results from the REIMAGINE studies of CagriSema, a combination of an amylin analogue and a GLP-1 agonist, showing significant reductions in HbA1c and body weight in type 2 diabetes patients. Phase 2 data for Zenagamtide (Amycretin) showed up to 89.1% of participants achieved A1C below 7%, and those on the highest dose lost up to 14.6% of body weight after 36 weeks. Phase 3 development for Zenagamtide is set to begin in H2 2026. CEO Mike Doustdar also stated the company is actively exploring GLP-1 applications in longevity research and aesthetic medicine, building on semaglutide’s organ-protective properties.
Regulatory and channel signals
The Medicare GLP-1 Bridge program launches on 1 July 2026, offering eligible beneficiaries with obesity access to injectable and oral Wegovy for a flat $50 monthly copay. The program has been extended through end of 2027. Novo Nordisk and Eli Lilly have agreed to supply GLP-1 drugs to Medicare at a net price of $245 per month, far below list prices. Doustdar targets roughly 15 million additional patients but notes access will open gradually.
Sourcing context
For overseas importers and distributors, the rapid uptake of oral Wegovy and the planned international rollout signal growing demand for GLP-1-based products in new markets. The company’s exploration of aesthetic medicine applications may open future supply opportunities for clinics and pharmacies. The Medicare expansion also indicates potential volume growth in the U.S. market, which could affect global supply allocation and pricing dynamics.
Source: Read the original report | Published: June 08, 2026